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Introduction: The aim of the study was to identify preoperative 
computed tomography (CT) imaging characteristics that correlated 
with surgical resectability.
Methods: We retrospectively reviewed the CT scans of 133 patients who 
underwent surgical resection for thymoma at our institution between July 
21, 1997, and September 22, 2010. Imaging characteristics recorded 
included tumor size, attenuation, contact of mediastinal vessels, tumor 
morphology, infiltration of surrounding fat, changes in the adjacent lung 
parenchyma, lymphadenopathy, and pleural involvement.
Results: The study group included 66 men and 67 women, aged 
23–88 years (mean 58.8 years). Eighty patients (60.2%) were 
Masaoka stage I or II and 53 (39.8%) were Masaoka stage III or 
IV. Twenty-three patients (17.3%) had an incomplete surgical resec-
tion. Of these, 15 patients had microscopic residual disease (11.2%) 
and eight had gross residual disease (6.0%). The preoperative CT 
characteristics that correlated with an incomplete surgical resection 
included a lobulated tumor contour (p = 0.016), greater than or equal 
50% abutment of the circumference of an adjacent vessel (p < 0.001), 
thoracic lymphadenopathy (p = 0.029), adjacent lung changes (p = 
0.005) and pleural nodularity (p = 0.001). Tumor size was larger in 
the incompletely versus completely resected groups, with mean val-
ues of 9.7 and 6.9 cm (p value 0.013). On multivariate analysis, only 
degree of abutment of adjacent vessels and pleural nodularity were 
independent predictors of incomplete resection.
Conclusions: Preoperative CT findings can predict the likelihood of 
successful surgical resection and could help to identify patients who 
might benefit from neoadjuvant chemotherapy.
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Thymomas are rare malignancies, accounting for less than 1% of primary malignancies in adults. The overall inci-
dence of thymoma is 0.15 cases per 100,000, according to data 
from the National Cancer Institution1 and small patient num-
bers make it a difficult disease to study. However, it remains 
the most common primary neoplasm of the anterior mediasti-
num, accounting for 20% of tumors in this location.2Surgical 
resection is the mainstay of treatment. Both early stage and 
appropriately managed advanced stage thymomas have excel-
lent prognoses. A complete surgical resection is considered to 
be the most important predictor of long-term survival3,4 and 
patients with early stage disease generally can be cured with 
surgery. Patients with locally advanced thymomas, however, 
can be challenging to resect, given the anatomic confines of 
the mediastinum, and often receive neoadjuvant chemother-
apy to improve resectability.5,6
Although a complete resection is the most important 
prognostic factor for thymic malignancies, the value of an 
incomplete resection, or debulking is questionable, particu-
larly in light of the fact that intergroup trials have suggested 
that chemoradiation can be effective management for unre-
sectable or recurrent disease. It is reasonable to consider that 
if radiographic predictors of incomplete resections can be reli-
ably identified; unnecessary or otherwise futile surgeries can 
be avoided. The objective of this study was to assess preopera-
tive computed tomography (CT) characteristics of thymomas 
and to correlate the imaging features with surgical resectabil-
ity. Our aim was to evaluate whether preoperative CT features 
could correctly identify those patients who subsequently had 
an incomplete surgical resection.
MATERIALS AND METHODS
Patient Selection
Our institutional review board granted approval and 
waived the requirement for informed consent for this retro-
spective study. The patients were identified from a prospec-
tively maintained database of surgical procedures. Patients who 
underwent a surgical resection for thymoma between July 1997 
and September 2010 were included if they had an initial stag-
ing CT scan available for review. Of these patients, those who 
had neoadjuvant chemotherapy before surgery were included 
only if a preoperative restaging CT scan was also available. 
Of 164 patients who had a thymoma resected in this period, 
31 were excluded for the following reasons: a preoperative CT 
study was not available for review (n = 24), the only available 
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preoperative CT study was obtained after neoadjuvant chemo-
therapy (n = 5) or no preoperative restaging CT was available 
after neoadjuvant chemotherapy (n = 1) and the only available 
CT slice thickness was 12 mm (n = 1). Clinical information 
was obtained retrospectively from electronic medical records.
Imaging Analysis
All initial staging CT scans were retrospectively 
reviewed by two radiologists (an oncologic imaging fellow 
and a junior thoracic radiologist), who were blinded to the 
clinical details and surgical outcome at time of image inter-
pretation. Where differences arose, they were resolved by a 
third more experienced thoracic radiologist (17 years of expe-
rience). The images were reviewed on a picture archiving and 
communications system (GE PACS; Waukesha, WI). Many of 
the patients had been referred from outside institutions to our 
tertiary referral center after initial imaging elsewhere, there-
fore CT protocols varied. The initial staging CT scans were 
performed on a range of multidetector CT scanners, with slice 
thickness varying from 1.5 to 8 mm. Most patients (n = 108, 
81.2%) had contrast enhanced CT scans.
For image interpretation, we used standard report terms 
defined by the International Thymic Malignancy Interest 
Group for anterior mediastinal masses suspected to be thy-
moma.7 The readers underwent a training session on the appli-
cation of these reporting criteria before starting the study, 
to limit bias. The CT features recorded included lesion size, 
location, contour, and attenuation.
Size was recorded in three axes: the longest axial dimen-
sion (x), the perpendicular short axis (y), and the maximum 
cranio-caudal dimension (y). Location for all tumors was in the 
prevascular anterior mediastinum. Lesion contour was defined 
as smooth or lobulated. The contour was considered smooth if 
there were no spiculations, lobulations, or poorly defined bor-
ders. A tumor was considered lobulated if one or more lobula-
tions were identified; lobulations were defined as convex tumor 
contours with adjacent notches between tumor lobules.
Tumor attenuation was described as homogeneous if 
the lesion was of uniform attenuation and as heterogeneous if 
there were areas of mixed attenuation within it. Lesions were 
assessed for the presence of calcifications, which, if pres-
ent, were classified as coarse, punctate, or linear. Infiltration 
of mediastinal fat was recorded, as was the presence of a fat 
plane between the tumor and adjacent mediastinal vessels. 
The percentage of tumor abutment of mediastinal structures 
was assessed and recorded as less than 10%, 10–25%, 25–
49%, 50–75% or greater than or equal to 75%.
Information regarding the surrounding structures was 
also documented, including the presence of adjacent lung 
changes, pleural effusion, pleural or pulmonary nodules, 
TABLE 1.  Patient Characteristics
Variables Number %
Age, mean (range), yr 58.8 (23–88)
Sex
  Male 66 50
  Female 67 50
Myasthenia gravis
  No 127 95
  Yes 6 5
Completeness of resection
  R0 110 83
  R1 15 11
  R2 8 6
WHO histologic type
  A 16 12
  AB 33 25
  B1 25 19
  B2 37 28
  B3 14 10
  Unknown 8 6
Masaoka stage
  I 34 26
  Ia 26 20
 IIb 20 15
  III 28 20
  IVa 19 14
  IVb 6 5
Maximum size of tumor
  Mean, range, cm 7.4 (SD 3.7), 1.5–18.8
Neoadjuvant chemotherapy
  Yes 49 37
  No 84 63
Adjuvant therapy
  None 97 73
  Radiotherapy 26 20
  Chemotherapy 5 4
  Chemoradiotherapy 3 2
  Unknown 2 1
TABLE 2.  Surgical Findings in Patients with R2 Resection
Patient Surgical Findings/Site of Residual Disease
1 Clear invasion of heart and left lung. Gross residual tumor left 
within the heart and left lung
2 Tumor involved pericardium and innominate/caval junction, 
surrounded the SVC and was adherent to anterior segment of the 
right upper lobe. Tumor invading through the pericardium and 
surrounding the aorta and SVC could not be completely resected.
3 Tumor had penetrated the pericardium and had infiltrated the 
adventitia of the aorta and left side of the aortic arch. Residual 
disease left around the aortic arch.
4 Tumor involved left phrenic nerve. As pulmonary metastases were 
identified at surgery, phrenic nerve sacrifice was not felt to be 
justified and residual tumor was left posterior to the phrenic nerve.
5 Extensive tumor involving both phrenic nerves, right hilum and all 
major mediastinal vessels. Full resection not attempted.
7 Tumor infiltrated SVC and left innominate vein. Thin sheet of 
tumor left on the innominate vein at the thoracic inlet.
7 Tumor invading left lung as far as hilum. Extrapleural 
pneumonectomy not attempted because of extensive patient 
comorbidities.
8 Mass encased SVC, left innominate vein and left hilum. Residual 
tumor at left hilum.
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lymphadenopathy, and findings suggesting distant metastatic 
disease.
In patients who had neoadjuvant chemotherapy, only 
the size of the tumor was recorded on the preoperative restag-
ing scan—other imaging features were not reassessed. The 
post-chemotherapy tumor size was recorded in three axes for 
these patients.
Statistical Analysis
We examined the associations between CT features and 
two binary outcomes: (1) complete or incomplete surgical 
resection (R1 or R2) and (2) early (I or II) versus late (III or 
IV) Masaoka stage. The percent of categorical features and 
mean with standard deviation (SD) of maximum tumor size 
on CT were summarized. Fisher’s exact test was used to test 
the univariate association between categorical variables and 
each binary outcome, and t test was used for maximum tumor 
size. A multivariable logistic regression was performed con-
structing the final model using backward selection with stay 
significance level at 0.05.
A test with p value less than 0.05 was considered statis-
tically significant. Statistical analyses were performed in soft-
ware package SAS 9.2 (SAS Institute Inc., Cary, NC).
RESULTS
Our study group consisted of 133 patients, with an even 
gender distribution (66 men and 67 women). Ages ranged from 
23 to 88 years, with a mean of 58.8 years. Ten patients (7.5%) 
had weight loss at time of presentation. Six patients (4.5%) had 
been diagnosed with myasthenia gravis. We assessed imaging 
features on a total of 133 initial staging CT scans and reassessed 
tumor size on 49 preoperative restaging CT scans in patients 
who received neoadjuvant chemotherapy. After surgery and 
pathological analysis, most patients were found to be an early 
Masaoka stage; 80 patients (60.2%) were Masaoka stage I or II 
and 53 (39.8%) were Masaoka stage III or IV (Table 1).
Twenty-three patients (17.3%) in the study group had 
an incomplete surgical resection. Of these, 15 (11.3%) had 
microscopic residual disease (R1), with involved surgical 
margins at pathology. Eight patients (6.0%) had macroscopic 
residual disease (R2) at time of surgery, mostly residual 
tumor around mediastinal vascular structures (Table 2). Most 
TABLE 3.  Resection Rates by Masaoka Stage
Masaoka Stage R0 (%) R1 (%) R2 (%)
I (n = 34) 33 (97) 1 (3) 0 (0)
IIa (n = 26) 24 (92) 2 (8) 0 (0)
IIb (n = 20) 20 (100) 0 (0) 0 (0)
III (n = 28) 23 (82) 3 (11) 2 (7)
IVa (n = 19) 9 (47) 5 (26) 5 (26)
IVb (n = 6) 1 (17) 4 (67) 1 (17)
TABLE 4.  Characteristics of Incompletely Resected Patients
Margin
Masaoka 
Stage
Neoadjuvant 
Chemotherapy
Maximum 
Preoperative 
Tumor Size 
(cm) Heterogeneity
Fat Plane 
Separating 
Tumor from 
Adj. Vessels
Peritumoral 
Fat 
Infiltration
% Abutment 
of Adj. 
Vessels
Adjacent 
Lung 
Changes
Pleural 
Effusion Lymphadenopathy
R1 IVb — 5.6 ✓ ✓ — 25–49% — — —
R1 IVa ✓ 6.5 ✓ — ✓ ≥75% — ✓ —
R1 IVa ✓ 6.3 ✓ — — 50–74% — — —
R1 IVb ✓ 7.5 ✓ — — 50–74% ✓ ✓ —
R1 III — 3.4 — — — 10–25% — — —
R1 IVa ✓ 14.0 ✓ — ✓ 50–74% ✓ ✓ —
R1 I — 6.0 — ✓ — 10–25% — — —
R1 IVa ✓ 18.5 ✓ — ✓ 25–49% ✓ ✓ —
R1 IIa — 5.5 ✓ — — 10–25% — — —
R1 IVa ✓ 7.5 ✓ — ✓ ≥75% ✓ — —
R1 III ✓ 10.0 ✓ — — 50–74% — ✓ —
R1 IIa — 5.5 ✓ — — 10–25% ✓ — —
R1 IVb ✓ 9.4 ✓ — — ≥75% — — —
R1 IVb ✓ 7.6 ✓ — — 25–49% — — —
R1 III — 4.5 ✓ — — 10–25% — — —
R2 IVa ✓ 18.8 ✓ — — ≥75% ✓ ✓ ✓
R2 IVa ✓ 10.4 ✓ — — ≥75% ✓ — —
R2 IVa ✓ 15.0 ✓ — — ≥75% — — —
R2 IVb ✓ 11.0 ✓ — — 50–74% ✓ ✓ ✓
R2 IVa ✓ 14.0 ✓ — — 50–74% ✓ — ✓
R2 III ✓ 12.0 ✓ — — ≥75% — — —
R2 IVa ✓ 17.0 ✓ — — ≥75% — — ✓
R2 III ✓ 10.0 ✓ — — ≥75% ✓ — —
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patients with an incomplete surgical resection were Masaoka 
stage III or IV (Tables 3 and 4).
Forty-nine patients in our study (36.8%) received neoadju-
vant chemotherapy. None received neoadjuvant radiation therapy. 
Seventeen of the 49 patients (34.7%) who had received neoad-
juvant chemotherapy had an incomplete surgical resection, with 
either microscopic (n = 9) or macroscopic (n = 8) residual dis-
ease. Eighty-four patients (63.2%) did not receive neoadjuvant 
TABLE 5.  Association of Preoperative Computed Thomography Features and Other Factors with Risk of Incomplete Surgical 
Resection
Complete Resection 
(n = 110)
Incomplete Resection 
(n = 23) Univariate Analysis Multivariable Analysisa
N (%) N (%)
Fishers Exact Test 
p Value
Odds Ratio (95% 
Confidence Interval) of 
Incomplete Resection p Value
Contour 0.016
  Lobular 66 (60%) 20 (87%)
  Round 44 (40%) 3 (13%)
Fat plane separating tumor from 
mediastinal vessels
0.078
  Yes 37 (34%) 3 (13%)
  No 73 (66 %) 20 (87%)
Infiltration of peritumoral fat 0.048
  Yes 31 (28%) 12 (52%)
  No 79 (72%) 11 (48%)
Degree of abutment of adjacent vessel 
circumference
<0.001 0.002
  <50% 97 (88%) 12 (52%) 1
  ≥50% 13 (12%) 11 (48%) 5.4 (1.9–15.5)
Adjacent lung changes 0.005
  Yes 14 (13%) 9 (39%)
  No 96 (87%) 14 (61%)
Right pleural effusion size >0.999
  <10% 106 (96%) 22 (96%)
  ≥10% 4 (4%) 1 (4%)
Left pleural effusion size >0.999
  <10% 107 (97%) 23 (100%)
  ≥10% 3 (3%) 0 (0%)
Presence of any pleural effusion 0.192
  Yes 14 (13%) 5 (22%)
  No 96 (87%) 18 (78%)
Mediastinal lymphadenopathy 0.138
  Yes 10 (9%) 5 (22%)
  No 100 (91%) 18 (78%)
Hilar lymphadenopathy 0.064
  Yes 3 (3%) 3 (13%)
  No 107 (97%) 20 (87%)
Any lymphadenopathy 0.029
  Yes 15 (14%) 8 (35%)
  No 95 (86%) 15 (65%)
Pleural nodularity 0.001 0.012
  Yes 11 (10%) 9 (39%) 1
  No 99 (90%) 14 (61%) 4.3 (1.4–13.1)
Pulmonary nodules 0.118
  Yes 14 (13%) 6 (26%)
  No 96 (87%) 17 (74%)
aFeatures without estimates were not included in the final multivariable model.
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chemotherapy, but six of these patients (7.1%) had an incomplete 
surgical resection—all had microscopic residual disease.
The median time interval between the initial staging CT 
scan and surgery was 1.7 months (range 0.03–48.2 months). 
Four patients had greater than 1 year interval between the 
initial staging CT scan and surgery. Among patients who 
received neoadjuvant chemotherapy, 92% of lesions decreased 
in size after chemotherapy. The mean change of tumor size 
was −16.8% (SD 26.7%, range −70.0% to 114.3%).
Several preoperative imaging features showed a sig-
nificant association with an incomplete surgical resection, on 
univariate analysis (Table 5). A lobulated tumor contour was 
encountered more frequently in patients who had an incom-
plete rather than a complete resection (p = 0.016). Most (87%) 
of the incompletely resected masses were lobular in contour. 
Most tumors described as round were completely excised (44 
of 47, 94%). The size of the tumors was larger in the incom-
pletely versus completely resected groups, with means of 
9.7 cm (SD 4.7) and 6.9 cm (SD 3.3), respectively (Wilcoxon 
rank sum test p value 0.013).
The relationship of the tumor to surrounding mediastinal 
fat and vessels was investigated. Twenty (87%) of the incom-
plete resected tumors had loss of a clear surrounding fat plane 
compared with 73 (66%) of the completely resected lesions, 
although this association was not statistically significant 
(p = 0.078). Several of the patients with gross residual disease 
after surgery had involvement of mediastinal vascular structures 
identified during surgery (Figs. 1–3; Table 2) and greater than 
or equal to 50% abutment of the circumference of an adjacent 
vessel on CT was statistically associated with an incomplete 
resection (p < 0.001). Multivariable analysis demonstrated an 
odds ratio of 5.4 of an incomplete resection in patients who had 
greater than or equal to 50% involvement of an adjacent vessel 
(95% confidence interval: 1.9–15.5, p = 0.002).
Most of the CT features that were associated with an 
increased risk of incomplete resection were also associated 
with late Masaoka stages (III or IV). Only five of 53 (9%) late 
stage patients had a round tumor; almost all were lobulated 
(p < 0.001). Most of the late stage patients had loss of adjacent 
fat planes (47 of 53 patients, 89%, p < 0.001) and over half 
(n = 29, 55%) had infiltration of peritumoral fat, compared 
with only 14% of early stage patients. Greater than or equal to 
50% abutment of the circumference of an adjacent vessel was 
also associated with late stage tumors (p < 0.001).
Changes in the lung parenchyma and pleura were more 
frequently identified on baseline CT scans in patients who 
had incomplete resections and were Masaoka stage III or IV. 
Adjacent lung changes were more common in incompletely 
resected patients (p = 0.005) and in late stage patients (p < 
0.001). Changes in the adjacent lung parenchyma were iden-
tified in only 8% of early stage patients, but were present in 
32% of the late stage patients (p < 0.001). The presence of a 
pleural effusion was associated with later stage (p < 0.001), 
but not with incomplete resection (p = 0.192). Patients with 
any pleural nodularity preoperatively were more likely to have 
FIGURE 1 A, B.  A 56-year-old man 
who presented with shortness of 
breath and facial swelling. Computed 
tomography revealed an infiltrative 
mediastinal mass, abutting greater 
than 75% of the circumference of the 
ascending aorta. At surgery, tumor 
had penetrated the pericardium and 
had infiltrated the adventitia of the 
ascending aorta and aortic arch. 
Gross residual tumor was left around 
the aorta.
FIGURE 2.  A 47-year-old man who complained of a pressure 
sensation in his head for a year. Computed tomography showed 
an anterior mediastinal mass, abutting the ascending aorta. At sur-
gery, the tumor invaded the pericardium, surrounding the aorta 
and superior vena cava, and could not be completely resected.
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residual disease after surgery (p = 0.001). The preoperative 
presence of pulmonary nodules was not significantly associ-
ated with incomplete resection (p = 0.118).
The presence of any thoracic lymphadenopathy sug-
gested an increased likelihood of incomplete resection on 
univariate analysis (p = 0.029) but was not an independent 
predictor on multivariable analysis. Neither mediastinal 
(p = 0.138) nor hilar (p = 0.064) lymphadenopathy on their 
own were significantly more prevalent in patients who had 
an incomplete resection. The presence of myasthenia gravis 
was not useful in predicting an incomplete resection or late 
Masaoka stage.
Of the six patients who had an R1 resection with-
out having received neoadjuvant chemotherapy; two-thirds 
(67%) had lobular-shaped tumors, two-thirds (67%) had no 
clear fat plane between the tumor and adjacent vessels, and 
two-thirds (67%) had heterogeneous tumor attenuation. None 
were described as having infiltration of peritumoral fat. Two of 
these patients had thoracic lymphadenopathy, one mediastinal 
and one hilar. These patients were equally divided into early 
(n = 3) and late Masaoka stage (n = 3).
The size of the tumors was significantly larger in the 
incompletely resected tumors than the completely resected 
lesions (means of 9.7 cm [SD 4.7] and 6.9 cm [SD 3.3], respec-
tively, p = 0.013) and was also significantly larger in late stage 
tumors than early stage (means of 9.6 cm [SD 3.9] and 5.9 cm 
[SD 2.8], respectively, p value < 0.001). On multivariate analy-
sis, only degree of abutment of adjacent vessels and pleural 
nodules were independent predictors of an incomplete resec-
tion (Table 5).
DISCUSSION
Although thymomas are the most common primary 
malignant tumor of the anterior mediastinum, their treat-
ment pathway has yet to be clearly defined. Complete surgical 
resection is the most important predictive factor for long-
term survival,3,4,8,9 but complete resection is not possible in 
all cases. Our study has shown that many of the imaging fea-
tures that have previously been associated with invasiveness 
of thymoma can be used to predict the risk of an incomplete 
surgical resection. Relationship of the tumor to mediastinal 
vessels on the initial staging CT scan was significantly associ-
ated with surgical resectability, even among the patients who 
subsequently received preoperative chemotherapy.
Neoadjuvant chemotherapy is widely used in the treat-
ment of thymomas, which are known to be chemosensitive 
tumors.10,11 Chemotherapy has been shown to be effective 
in treating locally advanced, metastatic, and recurrent thy-
momas.12–14 In chemotherapy-naïve patients, chemotherapy 
FIGURE 3 A–D.  A 65-year-old 
woman who presented with cough 
and dyspnea on exertion. At sur-
gery, the tumor was invading the 
left lung as far as the hilum. Several 
pleural metastases (arrow, C) and a 
metastasis on the right atrial append-
age (arrow, D) were also identified. 
An extrapleural pneumonectomy 
would have been required to resect 
all disease. This was not attempted 
because of patient comorbidities.
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regimens have achieved response rates between 50 and 90%. 
Most clinicians offer neoadjuvant chemotherapy to patients 
they consider to have more advanced stage disease, in an 
attempt to convert an unresectable tumor into resectable dis-
ease. However, the widely used Masaoka staging system can 
only be applied postoperatively. The WHO classification sys-
tem, which can be determined preoperatively, has been shown 
to have poor clinical reproducibility and correlation with 
long-term survival.15
The aim of this study was to establish characteristics that 
would preoperatively identify patients at risk of an incomplete 
resection, as they might benefit from neoadjuvant chemo-
therapy, or be better served by avoiding surgical management 
altogether. Of the incompletely resected patients in our study 
group, six had not received neoadjuvant chemotherapy. These 
patients all had some features that were associated in our anal-
ysis with an increased risk of incomplete resection. Tumor 
structure was of particular significance and all six patients all 
had a lobulated tumor contour.
Most of the features that were significantly associated 
with an incomplete surgical resection were also associated 
with late Masaoka stage, including tumor structure and size, 
peritumoral fat infiltration, mediastinal vessel abutment, and 
adjacent lung changes. These findings are similar to those in a 
study by Marom et al.16 who correlated many of these features 
on baseline imaging with higher Masaoka stage. Our findings 
underscore the importance of identifying such features on pre-
operative scans, as they can be used to predict an incomplete 
resection and higher stage tumors.
Current data mostly suggest that an incomplete thy-
moma resection or tumor debulking does not improve sur-
vival over a biopsy alone.17–19 However, a subtotal resection 
may decrease the size of the radiation field and radiation dose 
needed, reducing damage to surrounding organs.20,21 In some 
patients it may be prudent to avoid extensive surgery unless 
there is a reasonable chance of complete resection.
Limitations of our study include the nature of a retrospec-
tive study, with the associated inherent selection biases. Only 
patients who underwent a surgical resection were included, 
therefore some patients who were already judged to be unre-
sectable may have been excluded. Nevertheless, this analysis 
may be informative in guiding decision making because this 
cohort of patients were felt to be potentially resectable. The 
surgeon’s experience may have also affected the outcome for 
complete resection as patients were operated by different tho-
racic surgeons. The time interval between the initial staging 
CT scan and surgery varied considerably, greater than a year 
in several patients, and tumors may have altered in size and 
degree of mediastinal invasion within that time interval.
Slice thickness on the CT scans varied and the scans 
were performed on many different CT multidetector scan-
ners—this may have influenced evaluation of some of the 
features, particularly in assessing mediastinal fat planes 
and calcifications, which may have been affected by volume 
averaging. Some of the reporting terms were subjective in 
nature, which had the potential to introduce bias; however, 
the standardized report terms used were well defined, which 
limited the potential for subjectivity. The two reader model, 
with a more experienced reader available in cases where dif-
ferences arose, would have further reduced the impact of 
reader bias on this study.
We did not include stage or neoadjuvant therapy in 
our multivariate analysis with respect to incomplete resec-
tion, and we recognize that our series is too small to be 
able to adequately control for these issues. Many of the CT 
features found to be significant on univariate analysis were 
not independent predictors of incomplete resection on our 
multivariate analysis, probably because of small sample size 
limiting the power of the analysis to detect more significant 
associations.
Many of the patients received neoadjuvant chemother-
apy, which was shown to reduce tumor size in 92%, but this 
may have also altered some of the other tumor characteristics, 
which were not reassessed. However, our approach of corre-
lating only the pretreatment CT characteristics with the risk 
of incomplete resection is justified, as it is these initial staging 
scans that will influence a clinician’s decision to treat with 
neoadjuvant chemotherapy or not.
Many of the radiological features of thymomas that have 
previously been associated with invasiveness can be used to 
predict those at risk of an incomplete resection. These can aid 
in estimating the risk of an incomplete resection and help to 
select patients who may benefit from neoadjuvant chemother-
apy or nonsurgical management, ultimately guiding treatment 
decisions.
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